Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
February 6, 2018 6:51 AM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $52.00) while maintaining a Underperform rating.
Arfaei commented, "When the dust finally settles with the 1L-NSCLC data, we see a fragmented market with Merck's Keytruda... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c
February 5, 2018 7:02 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.31 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2018 EPS of $3.15-$3.30, versus the consensus of... More
